A Case of Patient with Lung Adenocarcinoma with Double Rare EGFR Mutation of G719C and L861Q.
- Author:
Jin Tak YUN
1
;
Gi Jun KIM
;
Shin Young KIM
;
Joon Won JEONG
;
Suk Young PARK
;
Young Jun YANG
;
Ji Chan PARK
Author Information
1. Department of Internal Medicine, Daejeon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Daejeon, Korea. sypark1011@hotmail.com
- Publication Type:Original Article
- Keywords:
Adenocarcinoma;
EGFR tyrosine kinase inhibitor;
Lung cancer;
Mutation
- MeSH:
Adenocarcinoma*;
Carcinoma, Non-Small-Cell Lung;
Exons;
Humans;
Lung Neoplasms;
Lung*;
Point Mutation;
Protein-Tyrosine Kinases;
Receptor, Epidermal Growth Factor
- From:Keimyung Medical Journal
2014;33(2):132-133
- CountryRepublic of Korea
- Language:English
-
Abstract:
The vast majority of epidermal growth factor receptor (EGFR) gene mutations are detected in lung adenocarcinoma. EGFR mutations are the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) treatment in patient with advanced non-small cell lung cancer. Of these, exon 19 deletions and exon 21 L858R point mutations account for more than 80% of mutations detected in tumor with EGFR mutations, which called classical EGFR mutations, and double mutations mainly composed of classical and uncommon EGFR mutations are reported to be present in 13% of total EGFR mutations. But there has been no report to date of patient with double mutation of TKI sensitive uncommon EGFR mutations (G719C and L861Q). We experienced a case of patient with lung adenocarcinoma with double mutation of G719C and L861Q, the first case on our literature review, and showing partial response to TKI treatment.
